BEIGENE LTD-ADR (BGNE)

US07725L1026 - ADR

156.39  +1.31 (+0.84%)

After market: 156.39 0 (0%)

News Image
a month ago - Seeking Alpha

FDA accepts BeiGene license application for gastric cancer combo therapy (NASDAQ:BGNE)

BeiGene's biologics license application for Tevimbra, a combination therapy for gastric cancer, has been accepted by the FDA, with a target action date set...

News Image
a month ago - Seeking Alpha

BeiGene gets EU backing for lung cancer therapy (NASDAQ:BGNE)

BeiGene receives positive CHMP opinion for tislelizumab, an anti-PD-1 treatment for non-small cell lung cancer, expanding its potential indications.

News Image
a month ago - Seeking Alpha

BeiGene GAAP EPS of -$3.53 beats by $0.38, revenue of $634.4M misses by $1.75M (NASDAQ:BGNE)

BeiGene reported fourth-quarter and full-year 2023 financial results, with a GAAP EPS of -$3.53, beating estimates by $0.38.

News Image
a month ago - InvestorPlace

Get Rich Quick With These 3 Biotech Stocks to Buy Now

The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.

News Image
2 months ago - BeiGene

Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

News Image
2 months ago - InvestorPlace

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

News Image
2 months ago - Market News Video

BeiGene Enters Oversold Territory (BGNE)

News Image
2 months ago - BeiGene Canada

Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

News Image
2 months ago - The Motley Fool

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

News Image
4 months ago - Seeking Alpha

BeiGene's multiple myeloma drug gets orphan drug status (NASDAQ:BGNE)

The U.S. FDA grants orphan drug designation to BeiGene's sonrotoclax for relapsed/refractory multiple myeloma treatment.

News Image
4 months ago - Seeking Alpha

BeiGene inks $1.33B deal for cancer drug (NASDAQ:BGNE)

BeiGene (BGNE) agrees to pay over $1B for exclusive global rights to a cancer candidate developed by Ensem Therapeutics. Read more here.

News Image
4 months ago - Seeking Alpha

BeiGene's Brukinsa gets Europe approval for follicular lymphoma (NASDAQ:BGNE)

BeiGene's drug, Brukinsa, has received EU approval for the treatment of follicular lymphoma, expanding its indication range in the region.